Diaceutics and Precision Cancer Consortium launch NGS concordance study for oncology biomarker testing
- Admin
- 2일 전
- 2분 분량
The collaborative initiative aims to generate evidence on the consistency of next-generation sequencing (NGS) testing across routine clinical laboratories, supporting future improvements in precision oncology diagnostics.
Diaceutics and the Precision Cancer Consortium (PCC) have launched an NGS Concordance Study to evaluate variation in genomic variant detection across next-generation sequencing panels and platforms used in routine clinical practice in the United States.
The study seeks to improve understanding of testing variability and generate evidence that could inform future discussions on biomarker testing quality, transparency and best practice in precision oncology.
Field | Content |
Alert Type | Industry Update |
Topic | Precision oncology diagnostics; biomarker testing; next-generation sequencing (NGS) |
Organisation(s) | Diaceutics PLC; Precision Cancer Consortium (PCC) |
Affected Stakeholders | Clinical laboratories, diagnostics companies, pharmaceutical and biotechnology companies, oncologists and precision medicine researchers |
Therapy Area(s) | Oncology |
Geography | United States |
What Happened | On 20 August 2026, Diaceutics and the Precision Cancer Consortium announced the launch of an industry-wide NGS Concordance Study. The study will evaluate up to 20 NGS assays currently used in routine clinical practice across US laboratories by comparing detected genomic variants against known reference profiles in synthetic samples. The initiative is an evidence-generation programme and does not introduce new regulatory requirements or testing standards. (Investegate) |
Why It Matters | As precision oncology increasingly relies on NGS to identify patients for targeted therapies, consistent and reliable biomarker testing is essential. The study is intended to improve understanding of differences between testing platforms and support more informed decisions about biomarker testing quality, although it is not designed to endorse specific assays or establish mandatory performance criteria. (Investegate) |
Supporting Context | The initiative builds on previous Diaceutics research highlighting improvements in biomarker testing alongside increasing complexity in the diagnostics landscape. The organisations plan to use the findings to support future scientific publications, conference presentations and broader industry discussions on testing concordance. (otp.tools.investis.com) |
Who Is Most Affected | Clinical laboratories performing NGS testing and diagnostics companies developing oncology assays are likely to be most directly affected, while pharmaceutical companies relying on biomarker-driven patient identification may also benefit from improved evidence on assay performance. (Investegate) |
Industry Impact | The findings could support future improvements in assay selection, testing transparency and quality assurance across precision oncology. Any broader changes to laboratory practice or industry standards would depend on how the evidence is adopted by stakeholders rather than the study itself. (Investegate) |
Key Takeaway | The NGS Concordance Study aims to strengthen confidence in routine oncology biomarker testing by generating comparative evidence on the performance of commonly used NGS assays. (Diaceutics) |
What to Watch | Recruitment of participating laboratories and diagnostics companies, publication of study findings, and whether the results influence future best-practice guidance or quality initiatives in precision oncology. (Investegate) |
Primary Source | |
Relevant Date | 20 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글